Device Trial Radar · NCT07943702
Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 13, 2026
Primary completion
Jan 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Dorian Technologies S.r.l.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- JSB Solutions S.R.L.
- First posted
- Nov 17, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies. The main questions it aims to answer are: * Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software? * Does using the software report change or refine the readers' classification compared with visual reading alone? * How usable do readers find the software? The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.
Conditions
- Parkinsonian Disorders
- Parkinson Disease
- Lewy Body Disease
- Movement Disorders
Interventions
DOlab software - DaT-SPECT workflowDevice
Investigational software (not CE-marked, class IIa) that automatically quantifies striatal 123I-ioflupane binding using four metrics (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) and compares them with a PPMI-based normative database. It is applied retrospectively to existing images, and its output is not used for patient care.
Visual interpretation (comparator)Diagnostic test
Visual reading of the same 123I-ioflupane images by blinded nuclear medicine physicians, scored 0-3 for the caudate, anterior putamen and posterior putamen of each hemisphere, according to the EANM/SNMMI guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Correlation between visual score and DOlab quantitative metricsTime frame: Phase 1 reading session, within 4 months of study start
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Azienda USL Toscana Centro - Ospedale Santo Stefano
Prato, Tuscany, Italy · Recruiting
Azienda Ospedale Università Padova
Padova, Veneto, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.